

# GxE contributions to cognitive aging: An MZ twin pair comparison

CHANDRA A. REYNOLDS<sup>1</sup> & NANCY L. PEDERSEN<sup>2,3</sup>

<sup>1</sup>UNIVERSITY OF CALIFORNIA, RIVERSIDE <sup>2</sup>KAROLINSKA INSTITUTET <sup>3</sup>UNIVERSITY OF SOUTHERN CALIFORNIA

## BACKGROUND

How GxE interactions affect aging processes are not well understood but evidence suggests GxE may shift over the life course [1]. GxE for cognitive decline may emerge after age 65 given increasing nonshared environment influences [2]. Genes in lipids and inflammatory/immune pathways may be particularly relevant.

- *APOE* maximally impacts Alzheimer's disease (AD) risk between 65-75 years [3], and likely cognitive decline [4].
- As *APOE* wanes, other genes or pathways may impact decline.
- Additional lipid and inflammatory/immune pathway genes have been identified [3], including *SORL1* [5].
- Comparing MZ within pair differences in cognitive change by genotypes may identify genes responsive to environments [2, 6-8].

## METHODS

### Participants (Analysis N = 1607)

#### SATSA: The Swedish Adoption/Twin Study of Aging

- Waves:  $M = 4.16$  ( $SD = 1.44$ ; Max 6 waves)
- Baseline Age:  $M = 64.75$  ( $SD = 8.08$ )
- $N = 671$  twins, 59% Female

#### GENDER: Sex Differences in Health and Aging Study

- Waves:  $M = 2.4$  ( $SD = 0.83$ ; Max 5 waves)
- Baseline Age:  $M = 74.44$  ( $SD = 2.63$ )
- $N = 446$  twins, 50% female


#### OCTO-Twin: Study of Origins of Variance in the Oldest-Old

- Waves:  $M = 3.67$  ( $SD = 1.36$ ; Max 5 waves)
- Baseline Age:  $M = 83.16$  ( $SD = 2.73$ )
- $N = 490$  twins, 63% female

$N = 269$  MZ pairs from the SATSA and OCTO-Twin samples.

$N = 198 - 216$  MZ complete pairs had genotyping plus cognitive data.

**Figure 1. Cognitive Trajectories: Full sample.**



**Outcomes:** Empirical Bayes estimates representing:

- Level @ 75 years
- Slope < 75 years
- Slope > 75 years

Growth models fitted to full information in SAS Proc Mixed (SAS, Cary NC). Data post-dementia onset excluded. Adjusted for practice effects. Rank-normalizations applied to adjust for non-normality.

**Table 1. (a) Genes in lipid, inflammatory, and related pathways; (b) *SORL1* risk set construction.**

Lipid	SNPs	Inflame	SNPs Related	SNPs	<i>SORL1</i> ***	Position	Tag	LD Spine
ABCA1	48	AGER	12	CDKN2A/B	2	rs11600875	120862178	1
ABCA2	1	APCS	11	FTO	2	rs923893	120870025	-
ACAT1	13	BDNF	11	HNX4	4	rs17245976	120870900	-
ACAT2	7	CHRM2	9	IDE	2	rs12364988	120872836	1
APOA1*	17	COMT	1	IGFBP2	2	rs668387	120873131	1
APOB	26	CRP	6	TCF7L2	2	rs753780	120875926	1
APOE	2	FAS	1	SORL1	15	rs688021	120876330	-
CETP	29	IL1A	10			rs7105365	120882005	1
CYP46A1	15	IL1B	9			rs641120	120886175	-
GALNT2	30	IL6	16			rs12285364	120898436	2
GCKR/XAB1	11	LTA	6			rs11512475	120902648	2
HMGCR	12	NR1H2	4			rs11820794	120913165	2
LCAT	6	NR1H3	11			rs2070045	120953300	3
LDLR	22	PLA2G2A	17			rs3824968	120981132	3
LIPC	40	PLA2G7	20			rs2282649	120984168	3
LIPG	16	PTGS2	12					
LPL	28	REST	2					
LRP1	19	SAA1	6					
MLXIPL/TBIL	13	SAA2	9					
PCSK9	24	SAA4	3					
PLTP	11	SELS	10					
SCARB1	32	SERPINA3	16					
SORT1*	11	SERPINE1	11					
SREBF1	5	TNF	7					
SREBF2	15							

\*APOA1 resides in cluster of APOA4/APOA3/APOA1.

\*\*SORL1 resides in cluster of CELSR2/PSRC1/SORT1.

\*\*\*Multilevel Logistic Regression in lme4 was fitted; empirical Bayes estimates saved [5]


## RESULTS

### I. Initial Test of GxE: Mixture distributions

An initial test of GxE using MZ pairs [2, 6] was conducted, testing for heterogeneity of within-pair differences in rank-normalized cognitive trajectory traits. A t-test was constructed from comparing mean squared pair differences vs. mean absolute pair differences squared:

$$t = \frac{h}{s} \quad h = \frac{d^2}{2} - \frac{\pi}{2} d^2 \quad s = \text{s.e.} = \frac{\sqrt{d^2}}{\sqrt{n}} (5321)$$

Analyses were weighted by inverse s.e. of growth parameters.




\*One-tailed t-tests were significant in Figure 2 if  $t > 1.66$  and suggestive of GxE.

### II. Evaluating *APOE* & *SORL1* associations


*APOE* e3/3 genotype shows greater variability in trajectories than e2/+ or e4/+ for Block Design ( $p_{MV} = .0350$ ), particularly for change before 75 (see Figure 3). Those with *APOE* e3/3 were 43% more variable ( $p = .0105$ ).

**Figure 3. *APOE* e3/3 vs. e2/+ & e4/+: Ratio of intrapair differences.**



*SORL1* risk sets predict variability with effects observed for sets 1-3 for Block Design (Wilks  $\Lambda = .91 - .96$ ,  $p = 0.0003 - 0.0474$ ), and set 3 for Synonyms (Wilks  $\Lambda = .96$ ,  $p = 0.0278$ ). Figure 4 presents set 3 effects from weighted multivariate regression analyses adjusted for all covariates (SAS Proc Reg, Cary NC).

**Figure 4. *SORL1* set 3 risk scores and intrapair differences for (a) Synonyms, (b) Block Design.**




Adjusted for sex, age, sex\*age, pair sums, *APOE* e4, and weighted by inverse standard errors.

## III. Association with lipid and inflammation candidates: controlling for *APOE* e4

Intrapair differences in trajectory features were subjected to association tests [8], using PLINK [9]. A 2-degree-of-freedom test was conducted agnostic to the genetic model for up to 620 SNPs. Figure 5 suggests other lipid pathway genes may be associated with variability in cognitive change after age 75 years.

### Figure 5.

#### Association: Intrapair differences in trajectories.



## CONCLUSIONS

- Responsiveness to environments, perhaps indicative of plasticity, is evident for cognitive change across domains.
- *APOE* e3/3 genotype shows greater variability in spatial trajectories especially before 75 years, consistent with prior work on semantic memory [2].
- Higher *SORL1* risk scores predict greater variability in verbal and spatial trajectories, particularly for risk set 3 capturing the 3' end of *SORL1*.
- Other lipid pathway genes may be important to consider for GxE after age 75 (e.g., *APOB*, *LRP1*, *LDLR*)
- Larger samples are needed, especially to evaluate sex effects. Follow-up is planned within IGEMS [10].

## ACKNOWLEDGEMENTS

Analytical work supported by NIA (AG037985). Genotyping supported by NIA (AG028555).

**SATSA**  
NIA (AG17561); AG04563; AG0175; AG7561)  
MacArthur Foundation Research Network on Successful Aging  
Aging  
Swedish Research Council (2007-2722; 2009-6141)  
Swedish Council for Working Life and Social Research (FAS) (97-047-18, 2009-0795)

**OCTO-Twin**  
NIA (AG08861)  
**GENDER**  
The Axel and Margaret Axson Johnson's Foundation  
Swedish Research Council  
Swedish Foundation for Health Care Sciences and Allergy Research

1. Reynolds, C. A., et al. (2015). Genetic and environmental contributions to cognitive aging and social factors. *Twin Res Human Genet*, 18(2), 141-154.  
2. Reynolds, C. A., et al. (2015). Genetic and environmental contributions to cognitive aging and social factors. *Twin Res Human Genet*, 18(2), 141-154.  
3. Reynolds, C. A. (2015). Alzheimer Disease and Environmental Influences. In: C. Reynolds, C. A. (Ed.), *Alzheimer Disease and Environmental Influences*. Academic Press, 128-133.  
4. Reynolds, C. A. (2015). Alzheimer Disease and Environmental Influences. In: C. Reynolds, C. A. (Ed.), *Alzheimer Disease and Environmental Influences*. Academic Press, 128-133.  
5. Reynolds, C. A. (2015). Alzheimer Disease and Environmental Influences. In: C. Reynolds, C. A. (Ed.), *Alzheimer Disease and Environmental Influences*. Academic Press, 128-133.  
6. Reynolds, C. A. (2015). Alzheimer Disease and Environmental Influences. In: C. Reynolds, C. A. (Ed.), *Alzheimer Disease and Environmental Influences*. Academic Press, 128-133.  
7. Reynolds, C. A. (2015). Alzheimer Disease and Environmental Influences. In: C. Reynolds, C. A. (Ed.), *Alzheimer Disease and Environmental Influences*. Academic Press, 128-133.  
8. Reynolds, C. A. (2015). Alzheimer Disease and Environmental Influences. In: C. Reynolds, C. A. (Ed.), *Alzheimer Disease and Environmental Influences*. Academic Press, 128-133.  
9. Reynolds, C. A. (2015). Alzheimer Disease and Environmental Influences. In: C. Reynolds, C. A. (Ed.), *Alzheimer Disease and Environmental Influences*. Academic Press, 128-133.  
10. Reynolds, C. A. (2015). Alzheimer Disease and Environmental Influences. In: C. Reynolds, C. A. (Ed.), *Alzheimer Disease and Environmental Influences*. Academic Press, 128-133.